Indegene’s wholly-owned subsidiary, Indegene Ireland Limited, has signed a Share Purchase Agreement to acquire 100% of the equity shares of Warn and Co Limited on October 16, 2025. Warn, based in the UK, specializes in providing business transformation consulting solutions within the life sciences sector. The acquisition aims to enhance Indegene’s capabilities and offerings in this domain, with the transaction expected to be completed by October 17, 2025.
Acquisition Announcement
Indegene Ireland Limited, a wholly-owned subsidiary of Indegene, has entered into a definitive agreement to acquire 100% of the equity shares of Warn and Co Limited. The Share Purchase Agreement (SPA) was signed on October 16, 2025, marking a significant step in Indegene’s expansion strategy.
Target Company Details
Warn and Co Limited, based in the UK, provides business transformation consulting solutions to clients primarily within the life sciences industry. For its last financial year (May 1, 2024 to April 30, 2025), Warn reported unaudited revenue of GBP 2.5 million.
Strategic Rationale
This acquisition is aimed at further enhancing Indegene’s capabilities and service offerings within the life sciences consulting business. By integrating Warn’s expertise, Indegene seeks to strengthen its position as a leading provider of specialized solutions in this sector.
Deal Terms and Expected Completion
The total purchase consideration is capped at GBP 3 million, subject to customary working capital adjustments. The transaction will be executed through an all-cash deal, including deferred performance and milestone-based components. The acquisition is expected to be completed on or before October 17, 2025.
Warn’s Business Overview
Warn provides transformational consulting services, including change management, organizational design, and solution design. The company was incorporated on May 10, 2013. Its reported turnover for the financial years are as follows:
- FY23: GBP 2.5 million
- FY24: GBP 2.0 million
- FY25: GBP 2.5 million
Source: BSE